China Resources Double-Crane Pharmaceutical Co Ltd Capital Reinvestment Ratio
China Resources Double-Crane Pharmaceutical Co Ltd capital reinvestment ratio. China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Capital Reinvestment Ratio of 0.39x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥487.90 Million) in capital expenditures (CN¥192.28 Million). See 600062 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of China Resources Double-Crane Pharmaceutical Co Ltd (1999–2024)
Capital reinvestment ratio of China Resources Double-Crane Pharmaceutical Co Ltd from 1999 to 2024. This chart tracks China Resources Double-Crane Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. See China Resources Double-Crane Pharmaceuti free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
China Resources Double-Crane Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (1999–2024)
China Resources Double-Crane Pharmaceutical Co Ltd capital reinvestment ratio by year from 1999 to 2024. For the full cash flow conversion analysis, see cash efficiency ratio of China Resources Double-Crane Pharmaceuti.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.35x | CN¥1.83 Billion | CN¥637.50 Million | ▼ -6.1% |
| 2023 | 0.37x | CN¥1.65 Billion | CN¥614.31 Million | ▼ -5.0% |
| 2022 | 0.39x | CN¥1.34 Billion | CN¥525.53 Million | ▲ +6.8% |
| 2021 | 0.37x | CN¥1.34 Billion | CN¥491.67 Million | ▲ +43.3% |
| 2020 | 0.26x | CN¥1.36 Billion | CN¥348.09 Million | ▲ +52.5% |
| 2019 | 0.17x | CN¥1.44 Billion | CN¥241.65 Million | ▲ +7.8% |
| 2018 | 0.16x | CN¥1.47 Billion | CN¥228.69 Million | ▲ +19.4% |
| 2017 | 0.13x | CN¥1.19 Billion | CN¥154.82 Million | ▼ -8.6% |
| 2016 | 0.14x | CN¥771.25 Million | CN¥110.04 Million | ▼ -40.6% |
| 2015 | 0.24x | CN¥701.35 Million | CN¥168.49 Million | ▲ +21.2% |
| 2014 | 0.20x | CN¥718.38 Million | CN¥142.38 Million | ▼ -50.3% |
| 2013 | 0.40x | CN¥546.24 Million | CN¥217.68 Million | ▼ -28.9% |
| 2012 | 0.56x | CN¥396.05 Million | CN¥221.89 Million | ▼ -15.4% |
| 2011 | 0.66x | CN¥511.53 Million | CN¥338.78 Million | ▼ -8.8% |
| 2010 | 0.73x | CN¥509.67 Million | CN¥370.18 Million | ▼ -12.9% |
| 2009 | 0.83x | CN¥342.01 Million | CN¥285.16 Million | ▼ -10.6% |
| 2008 | 0.93x | CN¥331.71 Million | CN¥309.20 Million | ▲ +61.2% |
| 2007 | 0.58x | CN¥235.46 Million | CN¥136.17 Million | ▲ +2.3% |
| 2006 | 0.57x | CN¥303.71 Million | CN¥171.66 Million | ▼ -37.9% |
| 2005 | 0.91x | CN¥139.78 Million | CN¥127.13 Million | ▲ +109.7% |
| 2004 | 0.43x | CN¥453.72 Million | CN¥196.84 Million | ▼ -82.8% |
| 2003 | 2.52x | CN¥148.94 Million | CN¥375.98 Million | ▲ +40.9% |
| 2002 | 1.79x | CN¥140.63 Million | CN¥251.99 Million | ▲ +43.9% |
| 2001 | 1.25x | CN¥141.01 Million | CN¥175.58 Million | ▲ +147.8% |
| 2000 | 0.50x | CN¥172.81 Million | CN¥86.83 Million | ▼ -5.4% |
| 1999 | 0.53x | CN¥131.54 Million | CN¥69.86 Million | — |